Healthcare resource utilization and costs assessment of type 2 diabetes patients initiating exenatide BID or glargine: a retrospective database analysis.

Journal of medical economics

Volumn 14, Issue 1, 2011, Pages 16-27

  Pawaskar, Manjiri ^a   Zagar, Anthony ^b   Sugihara, Tomoko ^b   Shi, Lizheng ^b  

^a ELI LILLY AND COMPANY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; DRUG DERIVATIVE; EXENDIN 4; GLARGINE; INSULIN; LONG ACTING INSULIN; PEPTIDE; VENOM;

ADOLESCENT; ADULT; ARTICLE; COST; ECONOMICS; FACTUAL DATABASE; FEMALE; HEALTH SERVICE; HUMAN; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; RETROSPECTIVE STUDY; UTILIZATION REVIEW;

ADOLESCENT; ADULT; COSTS AND COST ANALYSIS; DATABASES, FACTUAL; DIABETES MELLITUS, TYPE 2; FEMALE; HEALTH SERVICES; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN, LONG-ACTING; MALE; MIDDLE AGED; PEPTIDES; RETROSPECTIVE STUDIES; VENOMS; YOUNG ADULT;

EID: 82955198026     PISSN: None     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2010.544797     Document Type: Article

References (0)